Assessment of QoL and Outcomes with SBRT for RCC
Study Description
“Assessment of QoL and Outcomes With SBRT for RCC”
Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.
Location
Methods
No pharmaceutical medication involved
Recruiting patients only
Radiation - SBRT
35-40 Gy delivered in 5 fractions
Additional Information
Official Study Title
Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC
Clinical Trial ID
NCT03108703
ParticipAid ID
neg93b
